United States · Biotechnology startup
United States · MBX Biosciences
MBX Biosciences is a preclinical-stage biotech company that creates therapies to treat rare endocrine diseases.
Funding reportedLast round: Series C
Follow MBX Biosciences and see its new rounds in your feed.Start following
What company datasets say MBX Biosciences raised
Funding, as reported
Reported in all$238Min dollars
Rounds4
Last roundSeries C
Last round dateAug 2024
Investors listed13
SEC Form D$98M sold, 4 filings, last Nov 2022
Founders and team
From MBX Biosciences's own website and the SEC filings it signed: 12 on the team.
- Steve HoerterChairman & Chief Executive Officer
- Debra SojkaVice President, Regulatory Affairs
- Tyler CarnerVice President, Finance
- Jeff HeldChief Legal Officer
- John SmitherChief Financial Officer
- Karen BasbaumChief Business Officer
- Mark HopeChief Regulatory & Quality Officer
- Mark SouedChief Commercial Officer
- Michelle GrahamChief Human Resources Officer
- Peter Kent HawrylukExecutive Officer, Directori
- Richard Kent DiMarchiExecutive Officer, Directori
- Richard M. BartramExecutive Officeri
On the board, as filediCarl M. GordonEdward M. MathersJames M. Cornelius
On 3 portfolio pages
Investors who name them
Each firm lists MBX Biosciences on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
Biotechnology in United States
Startups like it
- SojournixWaltham · founded 2016Raised
- Receptor Life SciencesSeattle · founded 2017Raised
- Attune PharmaceuticalsNew York · founded 2018Raised
AbbVieNorth Chicago · founded 2012
GrailMenlo Park · founded 2015
EQRxCambridge · founded 2019- Cerevel TherapeuticsBoston · founded 2018
Royalty PharmaNew York · founded 1996
Is this your company?
Add your raise, your deck and your story, and put MBX Biosciences in front of investors. Or tell us what we have wrong.